Prelude Therapeutics annual shareholders’ equity
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Shareholders’ Equity Growth & History (PRLD)
Prelude Therapeutics's shareholders’ equity was $68.6M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $68.6M | −$62.8M | −47.79% |
| 2024 | 2024-12-31 | $131.5M | −$105.6M | −44.55% |
| 2023 | 2023-12-31 | $237.1M | $41.7M | +21.31% |
| 2022 | 2022-12-31 | $195.4M | −$90.5M | −31.64% |
| 2021 | 2021-12-31 | $285.9M | $73.7M | +34.74% |
| 2020 | 2020-12-31 | $212.2M | $261.6M | — |
| 2019 | 2019-12-31 | −$49.4M | — | — |
Prelude Therapeutics quarterly shareholders’ equity
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $133.7M | $57.9M | +76.34% |
| Q1 2026 | 2026-03-31 | $60.2M | −$43.0M | −41.67% |
| Q4 2025 | 2025-12-31 | $68.6M | −$62.8M | −47.79% |
| Q3 2025 | 2025-09-30 | $58.5M | −$97.9M | −62.58% |
| Q2 2025 | 2025-06-30 | $75.8M | −$106.4M | −58.39% |
| Q1 2025 | 2025-03-31 | $103.2M | −$107.6M | −51.04% |
| Q4 2024 | 2024-12-31 | $131.5M | −$105.6M | −44.55% |
| Q3 2024 | 2024-09-30 | $156.4M | −$81.8M | −34.34% |
| Q2 2024 | 2024-06-30 | $182.3M | −$79.8M | −30.44% |
| Q1 2024 | 2024-03-31 | $210.7M | $35.4M | +20.22% |
| Q4 2023 | 2023-12-31 | $237.1M | $41.7M | +21.31% |
| Q3 2023 | 2023-09-30 | $238.3M | $20.9M | +9.59% |
| Q2 2023 | 2023-06-30 | $262.1M | $21.2M | +8.81% |
| Q1 2023 | 2023-03-31 | $175.3M | −$86.5M | −33.04% |
| Q4 2022 | 2022-12-31 | $195.4M | −$90.5M | −31.64% |
| Q3 2022 | 2022-09-30 | $217.4M | −$93.8M | −30.15% |
| Q2 2022 | 2022-06-30 | $240.8M | −$93.5M | −27.97% |
| Q1 2022 | 2022-03-31 | $261.8M | −$94.8M | −26.57% |
| Q4 2021 | 2021-12-31 | $285.9M | $73.7M | +34.74% |
| Q3 2021 | 2021-09-30 | $311.2M | $82.9M | +36.33% |
| Q2 2021 | 2021-06-30 | $334.4M | — | — |
| Q1 2021 | 2021-03-31 | $356.6M | — | — |
| Q4 2020 | 2020-12-31 | $212.2M | $261.6M | — |
| Q3 2020 | 2020-09-30 | $228.3M | — | — |
| Q4 2019 | 2019-12-31 | −$49.4M | — | — |
Prelude Therapeutics shareholders’ equity trends
Over the last five fiscal years, Prelude Therapeutics's shareholders’ equity decreased from $212.2M to $68.6M, a change of −$143.5M. The latest reported quarter, Q2 2026, shows $133.7M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...